AbbVie Inc $48.55

up +0.43


17/4/2014 06:40 PM  |  NYSE : ABBV  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get ABBV Trend Analysis - it has underperformed the S&P 500 by 5%

Partner Headlines

  1. Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings

    IBD
  2. Has A Streamlined FDA Raised The Value Of Drug Stocks?

    IBD
  3. AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) ...

    Benzinga
  4. Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings

    Benzinga
  5. Benzinga's Top #PreMarket Losers

    Benzinga
  6. HCV Rivalry Heats Up As Merck Combo Shines In Trial

    IBD
  7. Merck Hepatitis C Combo Scores 98% Cure Rate

    IBD
  8. UPDATE: Morgan Stanley Reiterates, Removes PT on AbbVie on Potential of ...

    Benzinga
  9. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  10. Baxter Splitting In Effort To 'Unlock Trapped Value'

    IBD
  11. New Cholesterol Fighters To Take Center Stage At ACC

    IBD
  12. TripAdvisor: Yelp of Travel Looks Too Pricey

    YCharts
  13. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  14. House Probe Of Gilead's Sovaldi Price Hits Biotechs

    IBD
  15. Abbvie Inc. (ABBV) Dividend Stock Analysis

    GuruFocus
  16. Lountzis Asset Management Comments on Abbvie

    GuruFocus
  17. Gilead Pricing Probed By House; Biotech Stocks Drop

    IBD
  18. Gilead's HCV Challengers Near The Starting Gate

    IBD
  19. Gilead's HCV Challengers Near The Starting Gate

    IBD
  20. Horizon Pharma Banks On Two-For-One Arthritis Drugs

    IBD
  21. Novartis Vs. Everyone: Biologic Knockoffs

    YCharts
  22. Pharma Patent Cliff: Why Worst Seems Over

    YCharts
  23. UPDATE: Bank of America Reiterates on AbbVie on Higher HCV Sales

    Benzinga
  24. Investors Brace for Bear Market

    FoxBusiness
  25. AbbVie’s Testosterone: Impact of Health Concerns

    YCharts
  26. #PreMarket Primer: Friday, January 31: Emerging Market Turmoil Spills Over ...

    Benzinga
  27. Earnings Scheduled For January 31, 2014

    Benzinga
  28. We Were Dividends, Before Dividends Were Cool

    GuruFocus
  29. Abbott Labs Q4 Sales Miss Estimates; Earnings In Line

    IBD
  30. AbbVie Initiates Pivotal Phase 3 Study of Veliparib for Patients with Early-Stage ...

    Benzinga
  31. Enanta Joins Big Leagues With Hepatitis C Drug

    IBD
  32. BofA Merrill Lynch Reiterates on AbbVie, Raises PO

    Benzinga
  33. Biologic Makers Thwart Generics: Winning Stocks

    YCharts
  34. Drugmaker Aptalis Files For IPO After Overhaul

    IBD
  35. Benzinga's Top Downgrades

    Benzinga
  36. S&P Stocks Hitting New Highs

    FoxBusiness
  37. Co-Pays: Skin In the Game If It Ain’t Your Skin?

    YCharts
  38. Gilead's Next Hepatitis C Drug A Hit In Trials

    IBD
  39. Oversold ETFs Looking Attractive (IHE, CSD, PSCE)

    Benzinga
  40. UPDATE: Morgan Stanley Reiterates on AbbVie After Competitor's Schizophrenia ...

    Benzinga
  41. Drug trials cut new FDA path

    IBD
  42. Gilead knocked on drug price

    IBD
  43. Gilead HCV Drug May Face Price War; Rival AbbVie Up

    IBD
  44. Gilead Potential Blockbuster Hep C Drug Wins FDA Nod

    IBD
  45. 4 Potential Blockbuster Drugs Awaiting Launch

    IBD
  46. Market Wrap For December 3: Markets Finish In The Red For Third Straight ...

    Benzinga
  47. After Top-Seller Remicade: Analysis of J&J’s Future

    YCharts
  48. Gilead Hepatitis C Drug Wins EU Panel Vote Early

    IBD
  49. J&J’s Top Drug vs. Generic: Investment Thesis

    YCharts
  50. #PreMarket Primer: Friday, November 22: Draghi Defends ECB Rate Cut

    Benzinga
Trading Center